Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Immunologic Research
Erschienen in: Immunologic Research 4/2023

14.06.2023 | REVIEW

COVID-19 infection: a possible induction factor for development of autoimmune diseases?

verfasst von: Nikoo Saeedi, Narjes Sadat Farizani Gohari, Amir Ali Moodi Ghalibaf, Ali Dehghan, Mohammad Bagher Owlia

Erschienen in: Immunologic Research | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Following the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the importance of investigation of the pathogenesis and immunological characteristics of COVID-19 became quite clear. Currently, there are reports indicating that COVID-19 is able to induce autoimmune responses. Abnormal immune reactions are a cornerstone in the pathogenicity of both conditions. Detection of autoantibodies in COVID-19 patients may suggest a link between COVID-19 and autoimmunity. In this study, we focused on the similarities and possible differences between COVID-19 and autoimmune disorders to explore the relationship between them. Comparing the pathogenicity of SARS-CoV-2 infection with autoimmune conditions revealed significant immunological properties of COVID-19 including the presence of several autoantibodies, autoimmunity-related cytokines, and cellular activities that could be useful in future clinical studies aiming at managing this pandemic.
Literatur
1.
Wang C, Pan R, Wan X, Tan Y, Xu L, Ho CS, et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int J Environ Res Public Health. 2020;17(5):1729.PubMedPubMedCentralCrossRef
2.
Mahase E. China coronavirus: WHO declares international emergency as death toll exceeds 200. BMJ Brit Med J (Online). 2020;368.
3.
Thienemann F, Pinto F, Grobbee DE, Boehm M, Bazargani N, Ge J, et al. World heart federation briefing on prevention: Coronavirus disease 2019 (COVID-19) in low-income countries. Global Heart. 2020;15(1).
4.
5.
Chetaille Nézondet AL, Poubelle PE, Pelletier M. The evaluation of cytokines to help establish diagnosis and guide treatment of autoinflammatory and autoimmune diseases. J Leukoc Biol. 2020;108(2):647–57.PubMedCrossRef
6.
7.
8.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–8.PubMedPubMedCentralCrossRef
9.
Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17–41.PubMedCrossRef
10.
Rodríguez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve DM, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun. 2020;114:102506.PubMedPubMedCentralCrossRef
11.
12.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.PubMedPubMedCentralCrossRef
13.
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74.PubMedPubMedCentralCrossRef
14.
Hussein HM, Rahal EA. The role of viral infections in the development of autoimmune diseases. Crit Rev Microbiol. 2019;45(4):394–412.PubMedCrossRef
15.
Harley JB, James JA. Everyone comes from somewhere: Systemic lupus erythematosus and Epstein-Barr virus induction of host interferon and humoral anti-Epstein-Barr nuclear antigen 1 immunity. Arthritis Rheum. 2010;62(6):1571–5.PubMedPubMedCentralCrossRef
16.
Jog NR, Young KA, Munroe ME, Harmon MT, Guthridge JM, Kelly JA, et al. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Ann Rheum Dis. 2019;78(9):1235–41.PubMedCrossRef
17.
18.
Marino Gammazza A, Légaré S, Lo Bosco G, Fucarino A, Angileri F, Conway de Macario E, et al. Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: Possible role of molecular mimicry in COVID-19. Cell Stress Chaperones. 2020;25(5):737–41.
19.
Lucchese G, Flöel A. SARS-CoV-2 and Guillain-Barré syndrome: Molecular mimicry with human heat shock proteins as potential pathogenic mechanism. Cell Stress Chaperones. 2020;25(5):731–5.PubMedPubMedCentralCrossRef
20.
Venkatakrishnan AJ, Kayal N, Anand P, Badley AD, Church GM, Soundararajan V. Benchmarking evolutionary tinkering underlying human-viral molecular mimicry shows multiple host pulmonary-arterial peptides mimicked by SARS-CoV-2. Cell Death Discov. 2020;6(1):96.PubMedPubMedCentralCrossRef
21.
Kanduc D. From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry. Antibodies. 2020;9(3):33–8.
22.
Muller S, Radic M. Oxidation and mitochondrial origin of NET DNA in the pathogenesis of lupus. Nat Med. 2016;22(2):126–7.PubMedCrossRef
23.
Apel F, Zychlinsky A, Kenny EF. The role of neutrophil extracellular traps in rheumatic diseases. Nat Rev Rheumatol. 2018;14(8):467–75.PubMedCrossRef
24.
Wigerblad G, Kaplan MJ. NETs spread ever wider in rheumatic diseases. Nat Rev Rheumatol. 2020;16(2):73–4.PubMedCrossRef
25.
Ali RA, Gandhi AA, Meng H, Yalavarthi S, Vreede AP, Estes SK, et al. Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome. Nat Commun. 2019;10(1):1916.PubMedPubMedCentralCrossRef
26.
Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020;130(11):6151–7.PubMedPubMedCentralCrossRef
27.
McDonald B, Davis RP, Kim SJ, Tse M, Esmon CT, Kolaczkowska E, et al. Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice. Blood. 2017;129(10):1357–67.PubMedPubMedCentralCrossRef
28.
Englert H, Rangaswamy C, Deppermann C, Sperhake JP, Krisp C, Schreier D, et al. Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation. EBioMedicine. 2021;67:103382.PubMedPubMedCentralCrossRef
29.
30.
Bonaventura A, Vecchié A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol. 2021;21(5):319–29.PubMedPubMedCentralCrossRef
31.
32.
Northcott M, Jones S, Koelmeyer R, Bonin J, Vincent F, Kandane-Rathnayake R, et al. Type 1 interferon status in systemic lupus erythematosus: A longitudinal analysis. Lupus Sci Med. 2022;9(1):e000625.PubMedPubMedCentralCrossRef
33.
da Silva RP, Gonçalves JIB, Zanin RF, Schuch FB, de Souza APD. Circulating type I interferon levels and COVID-19 severity: A systematic review and meta-analysis. Front Immunol. 2021;12:657363.PubMedPubMedCentralCrossRef
34.
35.
Merrill JT, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020;16(10):581–9.PubMedPubMedCentralCrossRef
36.
37.
Setiati S, Harimurti K, Safitri ED, Ranakusuma RW, Saldi SRF, Azwar MK, et al. Risk factors and laboratory test results associated with severe illness and mortality in COVID-19 patients: A systematic review. Acta Med Indones. 2020;52(3):227–45.PubMed
38.
Ziadi A, Hachimi A, Admou B, Hazime R, Brahim I, Douirek F, et al. Lymphopenia in critically ill COVID‐19 patients: A predictor factor of severity and mortality. Int J Lab Hematol. 2021;43(1):38–43.
39.
Wang J, Li Q, Yin Y, Zhang Y, Cao Y, Lin X, et al. Excessive neutrophils and neutrophil extracellular traps in COVID-19. Front Immunol. 2021;43(1):e38–46.
40.
Satış H, Özger HS, Yıldız PA, Hızel K, Gulbahar Ö, Erbaş G, et al. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19. Cytokine. 2021;137:155302.PubMedCrossRef
41.
Vassallo M, Manni S, Pini P, Blanchouin E, Ticchioni M, Seitz-Polski B, et al. Patients with Covid-19 exhibit different immunological profiles according to their clinical presentation. Int J Infect Dis. 2020;101:174–9.PubMedPubMedCentralCrossRef
42.
Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. J Autoimmun. 2020;112:102473.PubMedPubMedCentralCrossRef
43.
Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20(4):102792.PubMedPubMedCentralCrossRef
44.
Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155–62.PubMedCrossRef
45.
Wang JY, Roehrl MW, Roehrl VB, Roehrl MH. A master autoantigen-ome links alternative splicing, female predilection, and COVID-19 to autoimmune diseases. J Transl Autoimmun. 2022;5:100147.PubMedPubMedCentralCrossRef
46.
Wang JY, Zhang W, Roehrl VB, Roehrl MW, Roehrl MH. An autoantigen-ome from HS-sultan B-lymphoblasts offers a molecular map for investigating autoimmune sequelae of COVID-19. bioRxiv. 2021;3(12):24–33.
47.
Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013;5(178):178ra40.
48.
Zuo Y, Yalavarthi S, Navaz SA, Hoy CK, Harbaugh A, Gockman K, et al. Autoantibodies stabilize neutrophil extracellular traps in COVID-19. JCI Insight. 2021;6(15):12–23.
49.
Torres-Ruiz J, Absalón-Aguilar A, Nuñez-Aguirre M, Pérez-Fragoso A, Carrillo-Vázquez DA, Maravillas-Montero JL, et al. Neutrophil extracellular traps contribute to COVID-19 hyperinflammation and humoral autoimmunity. Cells. 2021;10(10):32–44.
50.
Richter AG, Shields AM, Karim A, Birch D, Faustini SE, Steadman L, et al. Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection. Clin Exp Immunol. 2021;205(2):99–105.PubMedPubMedCentralCrossRef
51.
52.
Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and myositis: What we know so far. Curr Rheumatol Rep. 2021;23(8):1–16.CrossRef
53.
Gokhale Y, Patankar A, Holla U, Shilke M, Kalekar L, Karnik ND, et al. Dermatomyositis during COVID-19 pandemic (a case series): Is there a cause effect relationship? J Assoc Physicians India. 2020;68(11):20–4.PubMed
54.
Pascolini S, Granito A, Muratori L, Lenzi M, Muratori P. Coronavirus disease associated immune thrombocytopenia: Causation or correlation? J Microbiol Immunol Infect. 2021;54(3):531.PubMedCrossRef
55.
Rahi MS, Jindal V, Reyes S-P, Gunasekaran K, Gupta R, Jaiyesimi I. Hematologic disorders associated with COVID-19: A review. Ann Hematol. 2021;100(2):309–20.PubMedPubMedCentralCrossRef
56.
Nagu P, Parashar A, Behl T, Mehta V. CNS implications of COVID-19: A comprehensive review. Rev Neurosci. 2021;32(2):219–34.PubMedCrossRef
57.
Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: An update. Rev Endocr Metab Disord. 2021;22(4):803–15.PubMedCrossRef
58.
59.
Ismail II, Al-Hashel J, Alroughani R, Ahmed SF. A case report of multiple sclerosis after COVID-19 infection: Causality or coincidence? Neuroimmunol Rep. 2021;1:100008.CrossRef
60.
Ismail II, Al-Hashel J, Alroughani R, Ahmed SF. Association of multiple sclerosis and COVID-19 infection: A case report. MultScler Relat Disord. 2022;14(3):59–63.
61.
Rajdev K, Victor N, Buckholtz ES, Hariharan P, Saeed MA, Hershberger DM, et al. A case of Guillain-Barré syndrome associated with COVID-19. J Investig Med High Impact Case Rep. 2020;8:2324709620961198.PubMedPubMedCentral
62.
Rajdev K, Victor N, Buckholtz ES, Hariharan P, Saeed MA, Hershberger DM, et al. A case of Guillain-Barré syndrome associated with COVID-19. J Investig Med High Impact Case Rep. 2020;8:2324709620961198.PubMedPubMedCentral
63.
Palao M, Fernández-Díaz E, Gracia-Gil J, Romero-Sánchez C, Díaz-Maroto I, Segura T. Multiple sclerosis following SARS-CoV-2 infection. Mult Scler Relat Disord. 2020;45:102377.PubMedPubMedCentralCrossRef
64.
Zhou S, Jones-Lopez EC, Soneji DJ, Azevedo CJ, Patel VR. Myelin oligodendrocyte glycoprotein antibody–associated optic neuritis and myelitis in COVID-19.J Neuro-ophthalmol. 2020;12(2):23–9.
65.
Knack RS, Hanada T, Knack RS, Mayr K. Hashimoto’s thyroiditis following SARS-CoV-2 infection. BMJ Case Rep CP. 2021;14(8):e244909.CrossRef
66.
Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: Report of two cases of Graves’ disease after COVID-19. J Endocrinol Invest. 2020;43(10):1527–8.PubMedPubMedCentralCrossRef
67.
Trovato CM, Montuori M, Pietropaoli N, Oliva S. COVID-19 and celiac disease: A pathogenetic hypothesis for a celiac outbreak. Int J Clin Pract. 2021;75(9):e14452.PubMedCrossRef
68.
Guerra I, Algaba A, Jiménez L, Mar Aller M, Garza D, Bonillo D, et al. Incidence, clinical characteristics, and evolution of SARS-CoV-2 infection in patients with inflammatory bowel disease: A single-center study in Madrid, Spain. Inflamm Bowel Dis. 2021;27(1):25–33.PubMedCrossRef
69.
Bril F, Al Diffalha S, Dean M, Fettig DM. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty? J Hepatol. 2021;75(1):222–4.PubMedPubMedCentralCrossRef
70.
Bartoli A, Gitto S, Sighinolfi P, Cursaro C, Andreone P. Primary biliary cholangitis associated with SARS-CoV-2 infection. J Hepatol. 2021;74(5):1245–6.PubMedPubMedCentralCrossRef
71.
72.
Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, Elkord E. T-cell responses and therapies against SARS-CoV-2 infection. Immunology. 2021;162(1):30–43.PubMedCrossRef
73.
Koga T, Ichinose K, Kawakami A, Tsokos GC. Current insights and future prospects for targeting IL-17 to treat patients with systemic lupus erythematosus. Front Immunol. 2020;11:624971.PubMedCrossRef
74.
75.
76.
Cavalcante-Silva LHA, Carvalho DCM, de Almeida Lima É, Galvao JG, da Silva JSdF, de Sales-Neto JM, et al. Neutrophils and COVID-19: The road so far. Int Immunopharmacol. 2021;90:107233.
77.
78.
Muhammed L, Baheerathan A, Cao M, Leite MI, Viegas S. MuSK antibody-associated myasthenia gravis with SARS-CoV-2 infection: A case report. Ann Intern Med. 2021;174(6):872–3.PubMedCrossRef
79.
Kabeerdoss J, Danda D. Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists? Int J Rheum Dis. 2020;23(8):998–1008.PubMedPubMedCentralCrossRef
80.
81.
Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: A systematic review and meta-analysis. Ann Rheum Dis. 2021;80(3):384–91.
82.
83.
Cabanillas F, Morales J, Conde JG, Bertrán-Pasarell J, Fernández R, Hernandez-Silva Y, et al. Single-arm, open-label phase 2 trial of preemptive methylprednisolone to avert progression to respiratory failure in high-risk patients with COVID-19. medRxiv. 2021;23(4):33–9.
Metadaten
Titel
COVID-19 infection: a possible induction factor for development of autoimmune diseases?
verfasst von
Nikoo Saeedi
Narjes Sadat Farizani Gohari
Amir Ali Moodi Ghalibaf
Ali Dehghan
Mohammad Bagher Owlia
Publikationsdatum
14.06.2023
Verlag
Springer US
Erschienen in
Immunologic Research / Ausgabe 4/2023
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-023-09371-7

Weitere Artikel der Ausgabe 4/2023

Immunologic Research 4/2023 Zur Ausgabe

ORIGINAL ARTICLE

Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study

REVIEW

COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report

BRIEF REPORT

Case report: Synergistic defects of CASP10 and BTK leading to autoimmune lymphoproliferative syndrome type IIa, complicated by severe hemophagocytic lymphohistiocytosis

Review

Dysbiosis and primary B-cell immunodeficiencies: current knowledge and future perspective

Review

Autoinflammatory diseases and the kidney

ORIGINAL ARTICLE

Associations of IL-17 and IL-17 receptor polymorphisms with Behçet’s disease in Denizli Province of Turkey

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise